Thalassemia and autoimmune diseases: Absence of evidence or evidence of absence?

dc.contributor.authorEl-Hasbani, Georges
dc.contributor.authorMusallam, Khaled M.
dc.contributor.authorUthman, Imad W.
dc.contributor.authorCappellini, Maria Teresa
dc.contributor.authorTaher, Ali T.
dc.contributor.departmentInternal Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:43:56Z
dc.date.available2025-01-24T11:43:56Z
dc.date.issued2022
dc.description.abstractThe thalassemias are a group of inherited disorders of hemoglobin synthesis that continue to pause a global public health concern. The complex molecular and pathogenetic pathways involved in disease process lead to an array of comorbidities that require lifelong management. The disease and its treatment can also lead to alterations in immune function and a link to various autoimmune diseases has been frequently suggested. However, most data stem from single case reports and small studies that do not allow proper assessment of causal associations. Still, the high morbidity in thalassemia makes patients vulnerable to the added burden of coexisting autoimmune diseases, and special management considerations in this patient population are warranted. In this review, we explore insights and data from the literature on various autoimmune disease that have been observed in patients with thalassemia. The role of the thalassemia carrier state in modifying outcomes of patients with autoimmune diseases is also discussed. © 2021
dc.identifier.doihttps://doi.org/10.1016/j.blre.2021.100874
dc.identifier.eid2-s2.0-85112515140
dc.identifier.pmid34404565
dc.identifier.urihttp://hdl.handle.net/10938/30375
dc.language.isoen
dc.publisherChurchill Livingstone
dc.relation.ispartofBlood Reviews
dc.sourceScopus
dc.subjectAutoimmunity
dc.subjectManagement
dc.subjectPathophysiology
dc.subjectThalassemia
dc.subjectAutoimmune diseases
dc.subjectBeta-thalassemia
dc.subjectHumans
dc.subjectAnkylosing spondylitis
dc.subjectAntiphospholipid syndrome
dc.subjectAutoimmune disease
dc.subjectAutoimmune thrombocytopenia
dc.subjectCeliac disease
dc.subjectClinical feature
dc.subjectDisease severity
dc.subjectEvidence based practice
dc.subjectGraves disease
dc.subjectGuillain barre syndrome
dc.subjectHashimoto disease
dc.subjectHuman
dc.subjectIncidence
dc.subjectInflammatory bowel disease
dc.subjectInsulin dependent diabetes mellitus
dc.subjectMultiple sclerosis
dc.subjectPsoriatic arthritis
dc.subjectReview
dc.subjectRheumatoid arthritis
dc.subjectRisk factor
dc.subjectSystemic lupus erythematosus
dc.subjectBeta thalassemia
dc.subjectComplication
dc.titleThalassemia and autoimmune diseases: Absence of evidence or evidence of absence?
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2022-1941.pdf
Size:
544.04 KB
Format:
Adobe Portable Document Format